Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Amivantamab Plus Lazertinib or Chemotherapy in EGFR-mutant NSCLC (INSTAR)
NCT07507188Phase 2Not yet recruiting
- Sponsor
- Yonsei University
- Start
- Apr 2026
- Primary completion
- Jan 2031
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
01
Overview
A Phase 2 trial of amivantamab in non-small cell lung cancer (NSCLC), sponsored by Yonsei University. Planned start Apr 2026; status: not yet recruiting.
02
Drugs
amivantamab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT07507188.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07507188.